share_log

Transcode Therapeutics | PRE 14A: Preliminary proxy statements relating to merger or acquisition

Transcode Therapeutics | PRE 14A: Preliminary proxy statements relating to merger or acquisition

Transcode Therapeutics | PRE 14A：並購重組委托聲明
美股SEC公告 ·  2024/05/11 04:54

Moomoo AI 已提取核心訊息

TransCode Therapeutics, Inc. (TransCode), a biopharmaceutical company, has filed a preliminary proxy statement with the SEC, indicating plans to propose amendments to its certificate of incorporation and its 2021 Stock Option and Incentive Plan at its upcoming 2024 Annual Meeting of Stockholders. The proposed amendments include authorizing a reverse stock split of common stock at a ratio ranging from 1-for-2 to 1-for-40, at the discretion of the Board, to comply with Nasdaq's minimum bid price requirement. Additionally, the company seeks to increase the number of shares available for issuance under its 2021 Stock Option and Incentive Plan by 3,000,000 shares. The Annual Meeting is scheduled for June 13, 2024, at the offices of Goodwin Procter LLP in Boston, MA. The proxy statement also covers the election of four directors, the ratification of the appointment of WithumSmith+Brown, PC as the independent registered public accounting firm for the fiscal year ending December 31, 2024, and other business matters. The company will distribute the Proxy Statement for consideration in lieu of the Original Proxy Statement filed on April 29, 2024.
TransCode Therapeutics, Inc. (TransCode), a biopharmaceutical company, has filed a preliminary proxy statement with the SEC, indicating plans to propose amendments to its certificate of incorporation and its 2021 Stock Option and Incentive Plan at its upcoming 2024 Annual Meeting of Stockholders. The proposed amendments include authorizing a reverse stock split of common stock at a ratio ranging from 1-for-2 to 1-for-40, at the discretion of the Board, to comply with Nasdaq's minimum bid price requirement. Additionally, the company seeks to increase the number of shares available for issuance under its 2021 Stock Option and Incentive Plan by 3,000,000 shares. The Annual Meeting is scheduled for June 13, 2024, at the offices of Goodwin Procter LLP in Boston, MA. The proxy statement also covers the election of four directors, the ratification of the appointment of WithumSmith+Brown, PC as the independent registered public accounting firm for the fiscal year ending December 31, 2024, and other business matters. The company will distribute the Proxy Statement for consideration in lieu of the Original Proxy Statement filed on April 29, 2024.
生物製藥公司TransCode Therapeutics, Inc.（TransCode）已向美國證券交易委員會提交了初步委託書，表示計劃在即將舉行的2024年年度股東大會上提出對其公司註冊證書和2021年股票期權和激勵計劃的修正案。擬議修正案包括授權董事會根據納斯達克的最低出價要求對普通股進行反向分割，比例從1比2到1比40不等。此外，該公司尋求將其2021年股票期權和激勵計劃下可供發行的股票數量增加3,000,000股。年會定於2024年6月13日在馬薩諸塞州波士頓古德溫·寶潔律師事務所的辦公室舉行。委託書還涵蓋四名董事的選舉、批准任命Withumsmith+Brown, PC 爲截至2024年12月31日的財政年度的獨立註冊會計師事務所以及其他業務事項。該公司將分發委託書以供考慮，以代替2024年4月29日提交的原始委託聲明。
生物製藥公司TransCode Therapeutics, Inc.（TransCode）已向美國證券交易委員會提交了初步委託書，表示計劃在即將舉行的2024年年度股東大會上提出對其公司註冊證書和2021年股票期權和激勵計劃的修正案。擬議修正案包括授權董事會根據納斯達克的最低出價要求對普通股進行反向分割，比例從1比2到1比40不等。此外，該公司尋求將其2021年股票期權和激勵計劃下可供發行的股票數量增加3,000,000股。年會定於2024年6月13日在馬薩諸塞州波士頓古德溫·寶潔律師事務所的辦公室舉行。委託書還涵蓋四名董事的選舉、批准任命Withumsmith+Brown, PC 爲截至2024年12月31日的財政年度的獨立註冊會計師事務所以及其他業務事項。該公司將分發委託書以供考慮，以代替2024年4月29日提交的原始委託聲明。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    Enveric Biosciences
    ENVB
    -- 2.3000
    Renovaro
    RENB
    -- 1.190
    Moolec Science
    MLEC
    -- 0.850
    Salarius Pharmaceuticals
    SLRX
    -- 1.4500
    Channel Therapeutics
    CHRO
    -- 2.230
    解鎖完整榜單
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。
    熱門討論
    美聯儲暫停降息，你如何調整持倉？
    美聯儲宣布基準利率維持在4.25%—4.50%不變，符合市場預期。你會如何配置資產？ 展开
    FOMC新聞發佈會，2025年1月29日